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Abstract
Relatively little is known about the viral factors contributing to the lethality of the 1918 pandemic, although its unparalleled
virulence was likely due in part to the newly discovered PB1-F2 protein. This protein, while unnecessary for replication,
increases apoptosis in monocytes, alters viral polymerase activity in vitro, enhances inflammation and increases secondary
pneumonia in vivo. However, the effects the PB1-F2 protein have in vivo remain unclear. To address the mechanisms
involved, we intranasally infected groups of mice with either influenza A virus PR8 or a genetically engineered virus that
expresses the 1918 PB1-F2 protein on a PR8 background, PR8-PB1-F2(1918). Mice inoculated with PR8 had viral
concentrations peaking at 72 hours, while those infected with PR8-PB1-F2(1918) reached peak concentrations earlier,
48 hours. Mice given PR8-PB1-F2(1918) also showed a faster decline in viral loads. We fit a mathematical model to these
data to estimate parameter values. The model supports a higher viral production rate per cell and a higher infected cell
death rate with the PR8-PB1-F2(1918) virus. We discuss the implications these mechanisms have during an infection with a
virus expressing a virulent PB1-F2 on the possibility of a pandemic and on the importance of antiviral treatments.
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Introduction
The most deadly influenza pandemic documented occurred in
1918–1919 with over 40 million deaths worldwide [1]. The strain
responsible for this ‘‘Spanish Flu’’ pandemic was believed to have
caused significant primary viral pneumonia, although many
fatalities are attributed to secondary bacterial infections [2–4].
The unparalleled virulence experienced was probably due both to
strain novelty and to one or more intrinsic viral properties.
Present in nearly all influenza A virus (IAV) isolates, including
highly pathogenic avian strains [5], the newly discovered PB1-F2
protein is believed to have played a role in the extreme virulence of
the 1918 pandemic [6]. Found during a search for CD8z T-cell
epitopes, PB1-F2 is a small protein of 87–90 amino acids encoded
by an alternate reading frame of the PB1 gene segment [7].
Expression levels of this protein are variable in cells, and it has
been found localizing to mitochondria, although it is also present
in the cytoplasm and the nucleus [7–9]. IAV-induced apoptosis of
infected monocytes has been shown to occur with PB1-F2
expression, and is likely due to this protein’s ability to target and
interfere with mitochondrial functions [7,8,10]. The PB1-F2
protein is recognized by the human immune system leading to
both humoral and cell-mediated immune responses [7,11,12].
Furthermore, PB1-F2 can modulate the type I interferon response
in infected cells [13,14] and result in increased infiltration of
monocytes and neutrophils [13]. This was shown to be particularly
true for influenza viruses with an amino acid mutation in position
N66S in the PB1-F2 protein, which is characteristic of the 1918
strain [13]. Although PB1-F2 is not required for viral replication, it
was proposed that the efficiency of replication in epithelial cells
may be altered by PB1-F2 interacting with the viral polymerase
protein PB1 [15]. This effect, however, has been found to be
minor and depend on both cell type and virus strain, although
plaque size was significantly larger with a virus that expressed the
1918 PB1-F2 [16].
Using a PB1-F2 knock-out virus, decreased pathogenicity in
primary viral pneumonia resulting in rapid viral clearance was
demonstrated in a mouse model [17]. It has been found that a
single amino acid mutation in PB1-F2 of the 1918 pandemic strain
was sufficient to significantly affect the virulence of this virus
[13,18]. However, the effect of the PB1-F2 protein seems to be
dependent on both virus and host factors since knock-outs of PB1-
F2 on an A/WSN/33 (H1N1) virus (WSN) background did not
produce the same effects demonstrated using the A/Puerto Rico/
8/34 (H1N1) virus (PR8) [16,17,19]. We and others have found
that PB1-F2 induces large infiltrates of immune cells [6,13,19] and
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pneumonia in vivo, whereas PB1-F2 knock-out viruses show
decreased pathogenicity [6].
Using genetic information from a 1918 pandemic victim [20],
we engineered a virus to express the PB1-F2 protein from the 1918
strain, A/Brevig Mission/1/1918 (H1N1), with a PR8 background
[6]. The introduction of this 1918 PB1-F2 created a more deadly
virus which resulted in significantly increased viral titers in the first
32 hours compared to its isogenic parent, increased inflammation
and increased bacterial establishment and severity [6]. Connec-
tions between the mechanisms by which PB1-F2 enhances
pathogenicity in vivo and the in vitro functions, such as cellular
apoptosis and polymerase regulation, have recently been investi-
gated [16,19] but increased inflammation was the most consistent
effect of PB1-F2 [16].
To link mechanisms studied in vitro with their effects in vivo,
mathematical models can be used to tease apart the effect of virus
replication rates, virus half-life and infected cell life-spans.
Recently, several studies have used mathematical formulations to
describe influenza virus kinetics in a variety of experimental
systems (reviewed in ref. [21,22]). Target cell limited models have
been used in conjunction with nasal wash samples collected from
individuals infected with the influenza virus strains A/Hong
Kong/123/77 (H1N1) [23] and A/Texas/91 (H1N1) [24],
respectively, to estimate important viral kinetic properties
[25,26]. More complicated models have also been developed to
investigate the immune responses associated with influenza
infection. The adaptive immune response was the focus of one
study where mice were infected with H3N2 influenza virus A/
Hong Kong/X31 (X31) [27]. A follow-up investigation included a
more detailed experimental analysis and inclusion of components
of the innate immune response [28]. Another recent model was
used to describe an influenza A/equine/Kildare/89 (H3N8) virus
infection in Welsh ponies [29] to gain understanding of the
contributions of innate immunity and target cell depletion to
infection kinetics [30].
A similar set of models have been used to study an influenza
infection in vitro. These include infecting Madin-Darby canine-
kidney (MDCK) cells in a large-scale microcarrier culture with
equine influenza virus strain A/equine/Newmarket/1/93 (H3N8)
to estimate parameters by fitting a mathematical model to viral
measurements taken at various time points [31]. Another study
applied these models to viral titer data collected from a hollow-
fiber system in which MDCK cells were infected with the influenza
A/Albany/1/98 (H3N2) virus [32]. More recently, the kinetics of
three influenza viruses, the avian influenza A/Hong Kong/483/
97 (H5N1) virus, the seasonal influenza A/New Caledonia/20/99
(H1N1) virus, and the swine-origin influenza A/California/04/09
(H1N1), were modeled and compared using both differential
equation and cellular automata approaches with viral titer data
from infection of human differentiated bronchial epithelial cells in
an air-liquid interface culture [33].
Effectively applying mathematical models to fit data and
estimate parameters requires both accurate and frequent mea-
surements of viral loads. The choice of experimental system and
the variables measured can influence results. Human nasal wash
data provide viral titers over time in a set of individuals but sample
only the upper respiratory tract and do not directly assess the
lower respiratory tract where severe infections and pneumonia
occur. Furthermore, many nasal wash samples contain low titers
that cannot be detected, especially early in the infection. On the
other hand, in vitro samples provide insights into key features of
virus production but leave out important components, such as the
immune mediated effects, that occur during infection within a
host.
To address the influence of the 1918 PB1-F2 on in vivo infection
characteristics, we infected groups of BALB/c mice with one of
two influenza A viruses, A/Puerto Rico/8/34 (H1N1) and a
variant expressing the 1918 PB1-F2 protein, and obtained viral
measurements from the lungs of individual mice. These data
provide information on an infection occurring in the lower
respiratory tract. They allow us to compare the kinetics of two
virus strains over the course of infection to infer possible
mechanisms of PB1-F2 action.
We first analyze these data by comparing viral titers at various
times following inoculation. We use linear regression analysis to
determine the slopes of viral growth and decay. We then apply a
simple model to better quantify the dynamics of infection in vivo
and understand how the PB1-F2 protein of the 1918 pandemic
strain influences kinetics. Using this model, we estimate important
infection parameters and evaluate which components, such as
virus production or clearance, epithelial cell death, and/or
infectivity, are affected by expression of the 1918 PB1-F2. These
various analyses suggest which of the processes may be responsible
for the effects of PB1-F2 in vivo, and we evaluate the relation to
previously described mechanisms in vitro.
Results
Viral Titers of Mice Infected With Influenza PR8 or PR8-
PB1-F2(1918)
IAV lung titers, for both PR8 and PR8-PB1-F2(1918), initially
increase exponentially reaching peaks up to 3:2|108 TCID50=ml
lung homogenate. Mice inoculated with PR8 had viral titers
peaking at 72 hours postinoculation (p.i.) while mice given the PR8-
PB1-F2(1918) virus reached high titers (equivalent to the peak of
PR8) earlier at 48 hours p.i. (Figure 1). However, PR8-PB1-
F2(1918) titers remain high through 4 days p.i. with peak values
around 3:2|108 TCID50=ml lung homogenate. Titer differences
at 2 days and 4 days p.i. are statistically significant, pv0:001 and
pv0:01, respectively. Viral titers of both strains then decline as the
mice recover. All mice survived the experiment.
Kinetics of Virus Increase and Decline
Initially, viral titers drop as some virions are cleared while others
infect cells that enter an eclipse phase before virus production
occurs. After virus production begins, viral titers increase
exponentially then reach a peak and subsequently decay
exponentially. Because of the striking log-linear structure of the
Author Summary
Influenza A virus is a respiratory pathogen that causes
significant morbidity and mortality in infected individuals,
particularly during pandemics like the 1918–1919 Spanish
Flu pandemic. Recent data suggests that the influenza
virus PB1-F2 protein contributes to disease severity. Here,
we use data from infected mice together with quantitative
analyses to understand how the PB1-F2 protein from the
1918–1919 pandemic strain influences viral kinetics. We
find that the rates of virus growth and decay are increased
when the 1918 PB1-F2 is present. Our analyses suggest
that infection with an influenza virus possessing the 1918
PB1-F2 protein results in a higher rate of viral production
from infected cells and a higher rate of infected cell death.
These results provide new insights into the mechanisms of
PB1-F2 and the virulence and pathogenesis of pandemic
strains of influenza.
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to the rise and the other to the decline. By finding the two lines
that produce the maximum likelihood fit, the point where the
initial rise ends and the decline begins falls between 48 and
72 hours p.i. for both PR8 and PR8-PB1-F2(1918). We define
Phase I to be the viral dynamics occurring during the viral load
rise, typically the first 0–48 hours, and Phase II as the viral decline,
typically 3–9 days p.i. (Figure 2).
We find that Phase I runs from the time of inoculation until 2.6
days p.i. for PR8 and until 2.3 days p.i. for PR8-PB1-F2(1918).
Corresponding viral titers at the break points, which can be viewed
as imputed peaks, are 6:9 and 7:9 log10 TCID50=ml, respectively.
Using 5000 bootstrap replicates, we calculated the distributions of
peak viral titers and the times of these peaks (Figure 2). Using a
permutation test [34], we find that both the differences in the peak
timing and viral titer value at this peak are statistically significant
(p~0:025 and pv0:001, respectively).
In Phase I, the initial intercept value (0 days p.i.) is not significantly
different between PR8 and PR8-PB1-F2(1918) ({0:6 and
{1:2l o g 10 TCID50=ml, p~0:38, respectively) suggesting the initial
inoculum size reaching the lungs is similar for both strains. The slope
of PR8-PB1-F2(1918) viral titer increase is higher than that of PR8 by
1:1l o g 10 TCID50=ml day{1 (2:9l o g 10 TCID50=ml day{1 for
PR8 versus 4:0l o g 10 TCID50=ml day{1 for PR8-PB1-F2(1918),
pv0:05). Therefore, we find that viral titers increase more quickly
and reach a higher peak value when a PR8 virus containing the 1918
PB1-F2 is given.
In Phase II (3–9 days p.i.), extrapolated viral titers for the two
strains at both 3 and 9 days p.i. were not significantly different,
p~0:091 (6:8 versus 7:5l o g 10 TCID50=ml for PR8 and for
PR8-PB1-F2(1918), respectively) and p~0:096 (4:5 versus 3:8
log10TCID50=ml for PR8 and for PR8-PB1-F2(1918), respectively),
respectively. Nonetheless, our linear regression analysis of the Phase
II viral titer decay, which utilizes all the data between days 3 and 9,
suggests that the rate of viral clearance is enhanced in PR8-PB1-
F2(1918) infection by 0:2 log10 TCID50=ml day{1 ({0:4
log10TCID50=ml day{1 for PR8 versus {0:6 log10 TCID50=
ml day{1 for PR8-PB1-F2(1918), pv0:05). These results are
summarized in Table 1 and the best fit lines to PR8 and PR8-PB1-
F2(1918) viral titers are shown in Figure 2.
Estimation of Infection Parameters
Infection with PR8. We first fit Equations (4)–(7) to PR8
viral lung titers collected over 9 days to estimate model parameters
(Table 2). The fit is shown in Figure 3. When the eclipse phase
parameter k is not fixed, the maximum likelihood estimate lies
outside the biologically feasible range, 2ƒkƒ6 day{1 (4–
12 hours) [35,36]. Thus, we fixed k and set it at k~4 day{1 as
has been done previously [32,37], implying that the average
eclipse phase length, 1=k, is 6 hours.
Figure 1. Log10 values of viral titers per ml of lung homogenate from groups of 6–10 mice infected intranasally with 100 TCID50 of
influenza A virus PR8 (squares) or PR8-PB1-F2(1918) (triangles). Data are given as geometric means + SD. T-tests were used to determine
significance of differences of viral titers between these two strains for each time point,   pv0:001,  pv0:01.
doi:10.1371/journal.pcbi.1001081.g001
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cleared with rate constant c, then their average lifetime is 1=c.
During their lifetime, the average number of cells a virus infects is
bT0=c. We require that our parameter estimates satisfy bT0=cƒ1
so that, on average, each virion infects at most one cell.
The basic reproductive number, defined as
R0~
p
d
:bT0
c
, ð1Þ
is the product of the average number of virions produced during
the lifetime of an infected cell (p=d) and the average number of
cells infected per virion (bT0=c) [38]. The parameter estimates for
our fits for the infection with PR8 result in R0&28. Enforcing the
consistency condition produces parameters for which bT0=c&1
while p=d&1 (Table 3). The assays used measure only infectious
virus so these parameter values do not reflect the properties of
noninfectious virions.
We estimate the half-life (t1=2) of free infectious PR8 virus to be
0.6 hours. One study found that H3N2 influenza A virions lose
infectivity in vitro at a rate of 0.105 per hour, which corresponds to
a half-life of 6.6 hours [32]. If we assume PR8 loses infectivity at
approximately the same rate in vivo, then the majority of viral
clearance can be attributed to physical removal of viral particles
rather than loss of infectivity.
The average time a cell lives while infected with PR8, including
both the unproductive and productive stages, is approximately
33 hours. This value is significantly longer than previous estimates
of 11.4 hours for infection in the human upper respiratory tract
with an H1N1 virus [25] and 19.2 hours for infection in vitro with
an H3N2 virus [32].
Infection with PR8-PB1-F2(1918). Fitting Equations (4)–(7)
to PR8-PB1-F2(1918) viral titers, again fixing k~4 day{1 and
restricting bT0=cƒ1, produced parameter estimates different from
those for PR8 (Table 2). In particular, for PR8-PB1-F2(1918) we
estimate lower values for the infection rate constant (b), virus
clearance rate (c) and initial viral concentration (V0), and higher
values for the rate of virus production (p) and for the rate of
infected cell death (d).
Fitting the model to bootstrap replicates of the viral titer data for
each strain, the distributions of parameter values were obtained
(Figure 4). We find that the differences in the viral production rate
(p), the infected cell death rate (d) and the initial viral titer (V0) are
statistically significant (p~0:012, p~0:040, and p~0:021,
Table 1. Slopes, intercepts, peak times and peak values from linear regression analysis of PR8 and PR8-PB1-F2(1918) lung titers.
Phase I Peak Phase II
Slope log10 TCID50=
ml day{1
Day 0 Titer
log10TCID50=ml Time days
Titer log10
TCID50=ml
Slope log10
TCID50=ml day{1
Day 3 Titer
log10 TCID50=ml
Day 9 Titer
log10 TCID50=ml
PR8 2.89 20.64 2.62 6.93 20.38 6.79 4.52
PR8-PB1-
F2(1918)
4.0 21.17 2.27 7.91 20.62 7.46 3.75
p-value 0.032 0.38 0.025 v0:001 0.044 0.091 0.096
doi:10.1371/journal.pcbi.1001081.t001
Figure 2. Log-linear fits to lung viral titers in Phases I and II of an influenza infection with PR8 (solid line, squares) or PR8-PB1-
F2(1918) (dashed line, triangles). The number of data points included in each phase was determined by finding the two lines that produced the
maximum likelihood fit. No data point was allowed to be included in both phases. Distributions of peak times (days) and titers
(log10 TCID50=ml lung homogenate), PR8 - black and PR8-PB1-F2(1918) - gray, from bootstrap replicates of the log-linear fits.
doi:10.1371/journal.pcbi.1001081.g002
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plots the sets of parameters from fitting the bootstrap data in the
form of two-parameter projections (‘‘ensembles’’).
Cases in which the two ensembles overlap indicate that the data
and the model cannot distinguish those parameters between PR8
and PR8-PB1-F2(1918). These plots demonstrate the strong
correlation between the rate of cell infection (b) and the rate of
viral clearance (c) necessary to fit each data set. This correlation is
due to the imposed biological consistency condition, bT0=cƒ1.
Furthermore, constraining parameter values to lie within prede-
termined ranges (see Materials and Methods) yielded artificially
high bootstrap frequencies at the boundary values for estimates of
c for PR8 and of V0 for PR8-PB1-F2(1918) (Figures 4 and 5).
The estimate of the virus clearance rate, c, for PR8-PB1-
F2(1918) indicates a virus half-life of 1.8 hours, compared to
0.6 hours for PR8, implying that expression of the 1918 PB1-F2
may facilitate virion survival outside of the host cell. The
parameter estimates produce an infected cell lifespan of 22 hours
for PR8-PB1-F2(1918) versus 33 hours for PR8, suggesting that
the 1918 PB1-F2 may act either directly or indirectly to enhance
infected cell removal. Furthermore, the values of R0 differ between
PR8 (R0&28) and PR8-PB1-F2(1918) (R0&49). The maximum
Table 2. Maximum likelihood estimates of parameter values for influenza infection with PR8 and PR8-PB1-F2(1918).
V0 CID50=ml b (TCID50=ml)
1 day1|10{6 p TCID50 cell
{1 day{1 c day{1 d day{1
PR8 2.0 2.8 25.1 28.4 0.89
95% CI [0.6 8.4] [1.3 5.0] [19.9 58.0] [14.2 50.0] [0.6 1.3]
PR8-PB1-F2(1918) 0.26 0.91 72.8 9.2 1.5
95% CI [0.1 1.1] [0.3 3.4] [41.3 152.9] [3.1 50.0] [0.9 2.4]
For each virus strain, PR8 and PR8-PB1-F2(1918), the MLE initial viral titer (V0), infection rate constant (b), death rate of productively infected cells (d), viral release rate
per infected cell (p), and viral clearance rate (c). Initial number of target cells (T0) is fixed at 1|107 cells=ml lung homogenate, and the transition rate for infected cells to
produce virus (k) is fixed at 4d a y {1.
doi:10.1371/journal.pcbi.1001081.t002
Figure 3. Maximum likelihood fits of the viral kinetic model (Equations (4)–(7)) to lung titers from individual mice infected with the
PR8 virus (solid line, squares) or the PR8-PB1-F2(1918) virus (dashed line, triangles).
doi:10.1371/journal.pcbi.1001081.g003
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both PR8 and PR8-PB1-F2(1918) are given in Table 2 and the
model fits in Figure 3.
Connection between Virus Increase and Decline and
Infection Parameters
Both the linear regression analysis and the fits of the viral kinetic
model to the data show significant differences between virus
strains. To link these two analyses, we have investigated how the
estimated model parameters relate to the more easily computed
linear regression fits to the rising and falling portions of the viral
titer curve [39].
We previously derived approximate analytical solutions to
Equations (4)–(7) in the increasing (Phase I) and declining (Phase
II) portions of the viral kinetic curve [39]. This analysis showed
that the virus dynamics after the initial dip in viral titers can be
described by
Phase I V1(t)~a1elt ð2Þ
Phase II V2(t)~a2e{dtza3e{ctza4e{kt, ð3Þ
where l and the ai
0s are complex combinations of the parameters
(as given in ref. [39]). Using the parameter estimates in Table 2,
these expressions give an exponential growth parameter (l)o f
6:6 day{1 for PR8 and 9:3 day{1 for PR8-PB1-F2(1918), which
compare well with the direct estimates from the data (Table 4).
The approximate solution also provides an estimate of the
duration of the exponential growth phase (t1) [39]. With the
estimated parameters, this phase lasts for t1~2:1 days and
t1~1:8 days for PR8 and PR8-PB1-F2(1918), respectively. This
is approximately 0.5 days less than the peak times found via linear
regression, tpeak~2:6 days and tpeak~2:3 days, respectively. The
difference in these values represents the time between the slowing
of exponential growth and the time of the estimated peak,
suggesting that the growth of both PR8 and PR8-PB1-F2(1918)
starts to slow approximately 12 hours before the viral titer peaks.
In Phase II, V2(t) describes virus levels around the peak and the
decay throughout infection resolution (Equation (3)) [39]. All three
parameters in the exponents, d, c and k, are important in
determining the peak shape [39]. However, when the values of
these parameters are well separated, the smallest of these three
values, d for both PR8 and PR8-PB1-F2(1918) (see Table 2),
determines the slope of virus decay (as demonstrated in [39]). This
allows us to use the slope of the linear regression as an estimate of
the infected cell death rate. The value of d~0:87 day{1 and
d~1:42 day{1 for PR8 and PR8-PB1-F2(1918), respectively,
from the linear regression lie within the 95% confidence intervals
of the maximum likelihood estimated (MLE) values of
d~0:89 day{1 and d~1:47 day{1.
Discussion
We explored the in vivo kinetics of the mouse adapted PR8 and a
variant of PR8 that expresses the PB1-F2 protein from the 1918
influenza strain (PR8-PB1-F2(1918)) using both experimental and
mathematical models. The 1918 PB1-F2 protein differs by only 8
amino acids from that in the PR8 strain [6]. Since it may only
require a single amino acid mutation in PB1-F2 to influence
pathogenicity [13,18], PR8 and PR8-PB1-F2(1918) may differ
significantly in virulence. Furthermore, the 1918 PB1-F2 protein is
thought to have a direct role as a virulence factor during both
primary viral and secondary bacterial pneumonia [6].
Influenza viral titers in the lungs of the mice over the course of
an acute infection exhibit exponential growth for 2–3 days, then
briefly level out near the peak, and finally decline exponentially.
Lung titers in mice infected with each strain exhibit somewhat
distinct patterns of growth. The frequent sampling of these data
showed that the PR8-PB1-F2(1918) virus reaches significantly
higher titers as soon as 48 hours into the infection, with titers
remaining elevated for 2 days before finally declining. In contrast,
PR8 viral titers grow more slowly, reaching a peak at 72 hours p.i..
This rapid spread may indicate a potential for larger amounts of
viral shedding early on and lead to an increased probability of
effective transmission.
We also calculated the basic reproductive number, R0, which is
the average number of cells one infected cell will infect over its
lifetime when placed in a population of cells fully susceptible to
infection. R0 can be calculated from Equation (1). Our estimate of
the value of R0 for an infection with PR8 is large, R0&28, but the
value for an infection with PR8-PB1-F2(1918) is even larger
(R0&49). Both of these values are comparable to those estimated
from fitting the viral kinetic model to human nasal wash samples,
where R0 estimates ranged from 3.5 to 75 [25].
Quantifying the differences between infections with PR8 and
PR8-PB1-F2(1918) by fitting straight lines to what we term Phase I
(initial virus growth) and Phase II (virus decay from the peak) of
the log10 viral titer kinetics confirmed the higher rate of increase
and higher rate of decline of the PR8-PB1-F2(1918) virus and the
existence of an earlier and higher peak. Our analyses suggest that
viral growth generally slows 12 hours before a peak is reached
even when virus peaks are distinct, as was the case for PR8 and
PR8-PB1-F2(1918). The higher growth rate of PR8-PB1-F2(1918)
suggests that virus may either have a higher rate of cell infection
(b) or a higher rate of viral production (p) per infected cell.
However, using approximate solutions of the mathematical model
[39] in combination with the results from our model fits, we
determine that the increased growth rate of PR8-PB1-F2(1918) is
likely a consequence of increased viral production.
The more rapid decline of PR8-PB1-F2(1918) could be due to
more rapid death of infected cells (d). More rapid clearance of
virus (c) generally does not have a substantial effect on the net rate
of virus decline after the peak [39]. Despite the differences in viral
growth and decay rates, the lung viral titers shortly after the
estimated peak (3 days p.i.) and those near the end of infection are
similar between PR8 and PR8-PB1-F2(1918). Therefore, each
infection is cleared in roughly the same length of time.
Table 3. Infection characteristics for influenza infection with
PR8 and PR8-PB1-F2(1918).
t1=2 hrs StT hrs R0 p=db T0=c
PR8 0.6 32.9 27.8 28.2 0.99
95% CI [0.3 1.2] [24.5 46.0] [4.0 340.4] [15.3 96.7] [0.3 3.5]
PR8-PB1-
F2(1918)
1.8 22.3 48.9 49.5 0.99
95% CI [0.3 5.4] [16.0 32.7] [1.0 1863.3] [17.2 169.9] [0.1 11.0]
For each virus strain, PR8 and PR8-PB1-F2(1918), the virus half-life
(t1=2~ln(2)=c), infected cell lifetime (StT~1=kz1=d), basic reproductive
number (R0), average number of virions produced per infected cell (p=d), and
the average number of cells infected per infectious virion (bT0=c) are given
(parameter values used are in Table 2). The 95% confidence interval (CI) is given
below parameter estimates.
doi:10.1371/journal.pcbi.1001081.t003
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infection parameters allowed us to examine the differences in viral
kinetics due to the insertion of the 1918 PB1-F2 into PR8 in more
detail. Two parameters, the rate of viral production (p) and the
rate of infected cell death (d), emerged as the leading candidates
for the processes affected most by the presence of the 1918 PB1-
F2. However, there was some indication that V0, the amount of
virus initially reaching the lungs, is different between the two
viruses. We do not have a reason to believe that insertion of the
1918 PB1-F2 into PR8 would directly influence V0, and the
difference noted could be due to the simplified nature of the
model. However, PB1-F2 does cause inflammatory changes in the
lung [19], which in turn could affect viral distribution. Whether
this effect would occur early enough in the infection to correspond
to a change in V0 is unclear, but PB1-F2 is produced within the
first 6 hours of infection [16]. Furthermore, the clustering of V0 at
the lower bound for PR8-PB1-F2(1918) is surprising and suggests
that early data is inadequate to precisely estimate V0.
Figure 4. Distributions of the parameter values from bootstrap fits of the viral kinetic model (Equations (4)–(7)) to lung titers from
mice infected with PR8 (black) or PR8-PB1-F2(1918) (gray). Significant differences were detected in the viral production rate (p, p~0:012), the
infected cell death rate (d, p~0:040) and the initial viral titer (V0, p~0:021).
doi:10.1371/journal.pcbi.1001081.g004
Kinetic Effect of the 1918 Influenza PB1-F2
PLoS Computational Biology | www.ploscompbiol.org 7 February 2011 | Volume 7 | Issue 2 | e1001081For a wild-type PR8 infection, the viral kinetic model yielded an
estimate of the free virus half-life (t1=2~ln(2)=c) of 0.6 hours,
while t1=2 for PR8-PB1-F2(1918) was 1.8 hours. With large 95%
CIs, we could not detect a statistically significant difference
between the estimated values of the viral clearance rates (c).
However, these differences could indicate that expression of a
virulent PB1-F2, possibly corresponding to the N66S mutation
[13,18], decreases the clearance ability of the immune system.
Whether this is due to death of phagocytic cells, an effect on
mucocilliary clearance, or an effect on the possible decrease in
innate defenses caused by the 1918 PB1-F2 [13] cannot be
discerned from our modeling efforts. A competent immune system
is essential to clear virus as immunocompromised individuals can
exhibit persistent viral shedding [40]. PB1-F2 has been shown to
sensitize monocytes to proapoptotic stimuli [7,8,10], which could
explain an extended survival of PR8-PB1-F2(1918) outside of a
cell. Long lasting free infectious virus may have a greater chance to
infect cells, create a more severe infection and increase the
likelihood of transmission between hosts.
We note that the balance of a higher death rate of infected cells
and a larger production of virus leads to only minor differences in
the viral titers of these two infections [19], which we were able to
detect only due to the enhanced sampling of viral titers and the
kinetic modeling of the data. We have to interpret these results of
our modeling analyses in the context of our recent studies to
understand mechanistically the effect of PB1-F2, particularly from
the 1918 strain.
The influence PB1-F2 has on viral polymerase function [15],
although modest [16], could at least partially explain the higher
estimate of the per cell production, p, for the PR8-PB1-F2(1918)
virus. In a plaque forming assay, plaques generated by PR8-PB1-
F2(1918) virus were significantly larger than those generated by
PR8 [16], which would be consistent with a higher per cell
production rate. Since plaque assays only measure infectious virus,
an effect of PB1-F2 on the polymerase that increases the fraction of
infectious virions produced or accelerates viral production would
correspond to an increase in the infectious virus production rate, p.
However, this increased production could be due a delayed innate
immune response resulting from the ability of the 1918 PB1-F2 to
inhibit the type I interferon response in infected cells [13].
The 1918 PB1-F2 also seems to decrease the average survival
time of a productively infected cell (1=d) from 27 hours for PR8 to
Figure 5. Parameter ensembles from bootstrap fits of the viral kinetic model. Plots of the parameters, in the form of two parameter
projections of each fit, and the constraints (bottom left) from bootstrap fits of the viral kinetic model (Equations (4)–(7)) to lung titers from mice
infected with PR8 (red) or PR8-PB1-F2(1918) (blue).
doi:10.1371/journal.pcbi.1001081.g005
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virus effect is not known. Induction of cell death by PB1-F2 has
been shown to be strain-specific and not significantly increased
early in the infection with the 1918 PB1-F2 [19]. Since PB1-F2
may have maximum production 6–8 hours p.i. [16], the
differences in increased cell death we found may be an indirect
effect that occurs downstream. The associated cell damage may
then contribute to the immune cell infiltration that has been found
[6,13,19], however a direct link has yet to be established [19]. The
mechanism of cell death, whether directly caused by PB1-F2
within the cell or by an increased immune system response,
remains unclear.
Interestingly, in cell culture, replication of PR8 and PR8-PB1-
F2(1918) is similar [6]. This could be due to the combination of
effects our modeling has revealed. Cells infected with PR8-PB1-
F2(1918) could produce virus at a higher rate than cells infected
with PR8, but if such cells also lived a shorter time, the amount of
virus sampled in vitro at each time point could be similar for the
two viruses.
The immunopathology associated with the PB1-F2 protein has
recently been investigated and is thought to play a role during
influenza pathogenesis [19]. Enhanced inflammation in the
lungs, at least partially from an immune response dominated by
macrophage and neutrophil infiltration, has been shown
[6,13,19]. The mechanisms of immunopathology are unknown
but some studies suggest that PB1-F2 regulates pathways
involved in the innate immune response, particularly the
activation of type I interferon pathway genes [13,14]. The
model we use does not include specific host responses and is
unable to address the mechanisms involved in the increased
inflammatory response. A more complicated model involving
components of the immune system and quantitative measure-
ments of these cells and cytokines would be necessary and is a
focus of future work.
The viral kinetic model we use has previously been applied to
data collected from nasal wash samples in humans [25], in cell
culture [32] and now from murine lung samples. Parameter
estimates found in these studies differ (discussed in detail in [22]).
Here, when we imposed the condition that each virus, on average,
infects at most one cell such that bT=cƒ1, we found that the
average number of cells infected per infectious particle is close to
one at the initiation of infection when T~T0 and target cells are
most abundant. This suggests that once virus gets into the lung,
target cells are sufficiently plentiful that almost every infectious
virion finds a target cell to infect before being cleared.
The burst size from an influenza infected cell has been
estimated to be 18,755 virions (for infection of MDCK cells with
an equine influenza virus (H3N8)) [31], where approximately 1 in
100–500 virions are infectious [41,42]. If these values are accurate
for influenza viruses in general and we assume that 1 in 500 virions
is infectious, our findings that the average number of infectious
virions produced per cell (p=d) is 28 for PR8 and 49 for PR8-PB1-
F2(1918) suggest that the burst size for PR8 is 14,000 virions and
for PR8-PB1-F2(1918) is 24,500 virions.
Several variants of the model have been explored by us (results
not included) and others [32] to remedy possible violation of the
condition bT0=cƒ1. One model included a term for the loss of
free virus from infecting cells, such that the equation for free virus
becomes dV=dt~pV{cV{bTV. Including this term ensures
that the average number of cells infected per virion at the initiation
of infection (now bT0=(bT0zc)) is less than one, but the estimated
values of c became unrealistically large such that bT0zc in the
denominator once again became approximately equal to c. While
this attempt was unsuccessful overall, creating a more accurate
model formulation remains a focus of future work.
Here, we have shown how the 1918 PB1-F2 protein can have
significant effects on infection dynamics. Mathematical models can
be utilized to predict the behavior of this virus relative to PR8 and
link the biochemical, cellular, immunological, and population
levels. Furthermore, the equations describing viral growth and
decay (Equations (2)–(3)) can be easily used with results obtained
from the linear regressions providing a simple approach to
investigate certain aspects of infection without estimating param-
eters. Fully understanding the effects PB1-F2 has in various host
and virus contexts is crucial to successfully prepare for circulation
of a strain that may be only a single amino acid mutation away
from having pandemic potential.
Materials and Methods
Ethics Statement
All experimental procedures were approved by the Animal Care
and Use Committee at SJCRH under relevant institutional and
American Veterinary Medical Association guidelines and were
performed in a Biosafety level 2 facility that is accredited by
AALAAS.
Mice
Adult (6–8 wk old) female BALB/cJ mice were obtained from
Jackson Laboratories (Bar Harbor, ME). Mice were housed in
Table 4. Link between linear regression analysis and viral kinetic model estimates of the slope and length of viral growth (Phase I)
and the slope of virus decay (Phase II).
Analysis
Initial Viral Titer,
a1 TCID50=mlÞ ð
Slope of Exponential
Growth, l ðd1Þ
Length of Exponential
Growth, t1 ðdÞ
Slope of Exponential
Decay, d ðd1Þ
PR8 Approximate Solution/MLE 0.25 6.59 2.14 0.89
Linear Regression 0.23 6.65 2.62 0.87
D~0:48
PR8-PB1-F2(1918) Approximate Solution/MLE 0.067 9.26 1.80 1.47
Linear Regression 0.068 9.21 2.27 1.42
D~0:47
The MLE parameters in Table 2 were used in the approximate solution [39] of Equations (4)–(7) to find estimates of a1, l,a n dt1. The infected cell death rate (d)w a s
found to be the slope of exponential virus decay. The intercept value (0 days p.i.) (Table 1) is the effective initial titer and is an estimate of the constant a1 in Equation
(2). Values of the slopes found via linear regression (Table 1) were converted from log10 to loge for an accurate comparison.
doi:10.1371/journal.pcbi.1001081.t004
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15:2c mpolycarbonate cages with isolator lids. Rooms used for
housing mice were maintained on a 12:12-hour light:dark cycle at
22+20C with a humidity of 50% in the biosafety level 2 facility at
St. Jude Children’s Research Hospital (Memphis, TN). Prior to
inclusion in the experiments, mice were allowed at least 7 days to
acclimate to the animal facility. Laboratory Autoclavable Rodent
Diet (PMI Nutrition International, St. Louis, MO) and auto-
claved water were available ad libitum. All experiments were
performed in accordance with the guidelines set forth by the
Animal Care and Use Committee at St. Jude Children’s Research
Hospital.
Influenza Viruses
Viruses used in the experimental model consist of (i) the mouse
adapted influenza A/Puerto Rico/8/34 (H1N1) (PR8), and (ii) a
genetically engineered influenza virus referred to as ‘‘PR8-PB1-
F2(1918).’’ The latter virus, generated at St. Jude Children’s
Research Hospital, has a PR8 backbone with an eight amino acid
change in the PB1-F2 protein to match the protein from influenza
A/Brevig Mission/1/1918 (H1N1). For details on the construction
of this virus, see McAuley et al. (2007).
Infection Model
The dose infectious for 50% of tissue culture wells (TCID50) was
determined by interpolation using the method of Reed and
Muench [43] using serial dilutions of virus on Madin-Darby
canine kidney (MDCK) cells. For infection experiments, virus was
diluted in sterile PBS and administered at a dose of 100 TCID50
intranasally to groups of 6–10 mice lightly anesthetized with 2.5%
inhaled isoflurane (Baxter, Deerfield, IL) in a total volume of 100ml
(50ml per nostril). Viral measurements were obtained from samples
of individual lung homogenates at 8, 16, 24, 48, 72 hours p.i. and
4, 5, 7, 8 (PR8-PB1-F2(1918) only), 9 (PR8 only) days p.i.. Mice
were weighed at the onset of infection and each subsequent day for
illness and mortality.
Lung Titers
Mice were euthanized by CO2 asphyxiation. Lungs were
aseptically harvested, washed three times in PBS, and placed in
500ml sterile PBS. Lungs were mechanically homogenized using
the Ultra-Turrax T8 homogenizer (IKA-werke, Staufen, Ger-
many). Lung homogenates were pelleted at 10,000 rpm for
5 minutes and the supernatants were used to determine the viral
titer for each set of lungs using serial dilutions on MDCK
monolayers.
Linear Regression
We used the statistical programming language R [44] to
perform linear regression of the log10 values of viral titer during
the initial rise in viral titers and during the viral decay following
the peak. To determine the appropriate subset of data to include in
each of these phases, we used a maximum likelihood method to
find the optimum break point. We did not allow any data point to
be included in both phases.
Mathematical Model
We consider a target cell limited model that incorporates an
eclipse phase, originally presented in Baccam et al. (2006), to
describe IAV kinetics. We chose this model to analyze the viral
titer data because of its simplicity and its proven ability to estimate
parameters from viral titer data obtained from both human nasal
wash [25] and cell culture [32] infection systems. This model
depicts an influenza infection using four populations: susceptible
epithelial (target) cells (T), two sets of infected cells (I1 and I2), and
free virus (V). Target cells become infected at a rate bV per day.
Newly infected cells (I1) enter an eclipse phase before virion
production begins. This period tends to be rather short, e.g., 4–
6 hours, and for simplicity we assume no cell death occurs during
this period. Cells, I1, transition to productively infected cells (I2)a t
a rate k per day. Productively infected cells are lost (e.g., by
apoptosis, by viral cytopathic effects or by removal by immune
cells) at a rate d per day. The average total infected cell lifetime is
StT~1=kz1=d. Virus production occurs at a rate p per cell per
day, and virions are cleared at a rate c per day (t1=2~ln(2)=c is
the virus half-life). The following equations represent these
dynamics.
dT
dt
~{bTV ð4Þ
dI1
dt
~bTV{kI1 ð5Þ
dI2
dt
~kI1{dI2 ð6Þ
dV
dt
~pI2{cV ð7Þ
Data and models represent only infectious virus. Noninfectious
virus is not detected by the experimental assay used and is not
included in the model. We note that this model does not specify
mechanisms for a given process. For example, c and d encompass
viral effects and different immune mechanisms. Thus, it is possible
that some of the parameters change with time. Here, we assume
that all parameters are constant and explore how well this model
fits the observed viral titer data.
Parameter Estimation
Thecurve-fittingmethod we useisamaximumlikelihood estimation
(MLE) routine written in Matlab. We assume errors of the log10 titer
values are normally distributed. The negative log-likelihood is
minimized across parameter regimes using the Matlab minimization
subroutine (fmincon)a n dO D Es o l v e r( ode45) to compare experimental
and predicted values of log10 TCID50=ml lung homogenate.F i t
q u a l i t yi sd e t e r m i n e db yt h elog-likelihood (LL) value.
To more fully explore and visualize the regions of parameter
space consistent with the model and data for each strain and to
ensure that the minimum found by the MLE routine was a global
rather than a local minima, we use a second method that fits the
model to 1000 bootstrap replicates of each data set [34]. For each
bootstrap data set, ten fits are run starting from the overall best-fit
parameters and perturbing each parameter uniformly within
+50%. A bootstrap fit was considered successful if the three best
log-likelihood fits yielded values within 0.05. For each best-fit
estimate, we provide a 95% confidence interval (CI) computed
from the bootstrap replicates [34]. These calculations were
performed with the software package SloppyCell [45,46].
In our fits, we placed bounds on the parameters to constrain
them to physically realistic values. Since biological estimates are
not available for all parameters, we specified ranges that are
reasonably large based on previous estimates (reviewed in Ref.
[22]). We allowed the rate of infection, b, to vary between
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{1 day{1 and 1|10{5 (TCID50=ml)
{1
day{1, and the rate of viral production, p, to vary between
1|10{2 TCID50 cell
{1 day{1 and 5|102 TCID50 cell
{1
day{1. The rate of infected cell death, d, was given a lower limit
of 0:5 day{1, which corresponds to an average infected cell
lifespan of 48 hours, and an upper limit of 5 day{1, which
corresponds to an average infected cell lifespan of 4.8 hours. We
set the upper bound on the viral half-life (ln(2)=c) to be 8 hours
(i.e., c~2 day{1) and the lower bound to be 20 minutes (i.e.,
c~50 day{1). Previous estimates of c for influenza infection in
mice resulted in c~4:2 day{1 [28], and estimates for other
viruses, such as HIV (c~23 day{1 [47]) and hepatitis C virus
(c~6 day{1 [48]), are in the given range. For the initial viral
concentration, V0, a lower limit of 0:1 TCID50=ml was imposed.
Given that a typical lung homogenate is 1–1.5 ml (observed from
our experiments), we chose this value since at least one infectious
virion is required to initiate an infection and by naively assuming
that one or a few infectious virions correspond to a TCID50. The
upper limit on V0 was set to 100 TCID50=ml.
In each fit, the initial number of target cells, T0, is fixed.
Stafford et al. (2000) [49], in the context of an HIV model, showed
that it is not possible to estimate both the rate of virus production,
p, and the initial number of target cells, T0, as the model solution
involves only the product pT0. A similar calculation can be done
using Equations (4)–(7); therefore, we have chosen to fix T0 and let
the viral production parameter p vary in our estimations. We fixed
T0~1|107 cells=ml lung homogenate based on an estimate of
the total number of type I and type II epithelial cells in the alveolar
region of the murine lung [50], and the fact that the total volume
of lung homogenate is about 1 ml. The initial number of target
cells needs to be given as a density so that units in the model are
consistent. By fixing T0 at this value, we are assuming that not all
lung epithelial cells are targets for infection. It is possible that some
cells are not targets, say due to lack of access of the virus or due to
innate immune responses [30].
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